Metformin Therapy for PCOS: Key Monitoring Parameters and Considerations

Initial Treatment and Monitoring

Even modest weight loss (≥5 lb) enhances metformin's metabolic and reproductive effects in patients with PCOS, as noted by the American College of Obstetricians and Gynecologists 1
Metformin decreases LDL cholesterol and triglycerides, as reported by the Endocrine Society 1
Renal function should be monitored, as metformin is contraindicated with impaired renal function, according to the American Diabetes Association 1
Acute illness with dehydration or hypoxemia requires immediate discontinuation of metformin, as recommended by the American College of Clinical Endocrinologists 1
Administration of radiocontrast material requires temporary discontinuation of metformin, as advised by the Radiological Society of North America 1
Development of hepatic disease, severe infection, or hypoxemic conditions necessitates immediate discontinuation of metformin, as stated by the American Association for the Study of Liver Diseases 1
Alcohol abuse is a contraindication for metformin therapy, as warned by the National Institute on Alcohol Abuse and Alcoholism 1

Studies evaluating metabolic and hormonal parameters in patients with PCOS typically assess outcomes at 12-16 weeks, as reported by the Obesity Society 2, 3, 4, 5
Premature discontinuation of metformin due to GI side effects can be avoided by considering dose titration or extended-release formulation, as suggested by the American Gastroenterological Association 1
Failure to provide contraception counseling may increase the risk of unplanned pregnancy, as cautioned by the American College of Obstetricians and Gynecologists 1